289715-28-2

Usage

Uses

Used in Pharmaceutical Industry:
CB 300919 is used as a pharmaceutical compound for its potential therapeutic applications. Its unique properties and complex structure make it a candidate for the development of new drugs, targeting a variety of medical conditions.
Used in Polymer Industry:
CB 300919 is used as a component in polymer formulations for enhancing the properties of polymers. Its incorporation can improve characteristics such as strength, flexibility, and durability, leading to the creation of advanced materials for diverse applications.
Used in High-Value Chemical Applications:
CB 300919 is used as a key ingredient in the production of high-value chemicals, where its unique properties contribute to the performance and quality of the final products. This includes applications in specialty chemicals, fine chemicals, and other sectors that require high purity and specific functionalities.
Used in Research and Development:
CB 300919 is used as a subject of research for exploring its potential in various scientific and technical fields. Its complex structure and unique properties provide a basis for innovative studies, which may lead to new discoveries and applications in different industries.

Upstream product

• 3731-52-0 3-Aminomethylpyridine 
• 109-01-3 1-methyl-piperazine 
• 289686-90-4 tert-butyl 4-[N-[7-chloro-3-methyl-2-(4-methylpiperazin-1-ylmethyl)-4-oxo-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl)amino]benzoate 
• 289686-87-9 tert-butyl 4-[N-[2-acetoxymethyl-7-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl)amino]benzoate 
• 289686-86-8 2-acetoxymethyl-6-bromomethyl-7-chloro-3-methyl-3,4-dihydroquinazolin-4-one 
• 289686-85-7 2-acetoxymethyl-7-chloro-3,6-dimethyl-3,4-dihydroquinazolin-4-one 
• 289686-84-6 2-acetoxymethyl-7-chloro-6-methyl-3,4-dihydroquinazolin-4-one 
• 458533-73-8 2-methoxyacetamido-4-chloro-5-methyl N-methylbenzamide 
• 458533-71-6 methyl 2-methoxyacetamido-4-chloro-5-methylbenzoate 
• 289686-83-5 7-chloro-2-chloromethyl-6-methyl-3,4-dihydroquinazolin-4-one 
• 458533-75-0 2-methoxymethyl-7-chloro-3,6-dimethyl-3,4-dihydroquinazolin-4-one 
• 458533-77-2 2-hydroxymethyl-7-chloro-3,6-dimethyl-3,4-dihydroquinazolin-4-one 
• 458533-67-0 7-chloro-6-methyl-1H-benzo[d][1,3]oxazine-2,4-dione 
• 458533-69-2 methyl 2-amino-4-chloro-5-methylbenzoate 

Downstream Products

• 289715-34-0 4-[N-[7-chloro-3-methyl-2-(4-methyl-piperazin-1-yl)methyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl)amino]-N-(3-pyridylmethyl)benzamide hydrochloride salt 

Relevant academic research and scientific papers

Analogues of 4-[(7-Bromo-2-methyl-4-oxo-3 H -quinazolin-6-yl)methylprop-2- ynylamino]- N -(3-pyridylmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt)

We have shown previously that the target of the potent cytotoxic agent 4-[(7-bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino] -N-(3-pyridylmethyl)benzamide (CB38065, 1) is nicotinamide phosphoribosyltransferase (Nampt). With its cellular target known we sought to optimize the biochemical and cellular Nampt activity of 1 as well as its cytotoxicity. It was found that a 3-pyridylmethylamide substituent in the A region was critical to cellular Nampt activity and cytotoxicity, although other aromatic substitution did yield compounds with submicromolar enzymatic inhibition. Small unsaturated groups worked best in the D-region of the molecule, with 3,3-dimethylallyl providing optimal potency. The E region required a quinazolin-4-one or 1,2,3-benzotriazin-4-one group for activity, and many substituents were tolerated at C2 of the quinazolin-4-one. The best compounds showed subnanomolar inhibition of Nampt and low nanomolar cytotoxicity in cellular assays.

Anti-quinazoline compounds

Dihydroquinazoline derivatives of the formula where R3is —(CH2)p—A where p is from 1 to 4 and A is a 5- or 6-membered N-containing heterocyclic ring attached via the N atom or A is —NA′A″ wherein A′ and A″ are the same or different and are each a C1-C4alkyl group or their pharmaceutically acceptable salts possessing anti-cancer activity.

The design and synthesis of water-soluble analogues of CB30865, a quinazolin-4-one-based antitumor agent

4-[N-[7-Bromo-2-methyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl] -N-(prop-2-ynyl)amino]-N-(3-pyridylmethyl)benzamide (CB30865) is a quinazolin-4-one antitumor agent whose high growthinhibitory activity (W1L2 IC50 = 2.8 ± 0.50 nM) is believed to have a folate-independent locus of action. In addition, CB30865 represents a class of compounds with unique biochemical characteristics such as a delayed, non-phase specific, cell-cycle arrest. The low aqueous solubility of CB30865 prompted a search for more water-soluble analogues for in vivo evaluation of this class of compounds. It was thought that aqueous solubility could be increased by the introduction of amino functionalities at the 2-position of the quinazolin-4-one ring. A variety of compounds (5a-j, 31a-c, 32, and 33) were synthesized in a linear fashion starting from 3-chloro-4-methylaniline. Most of these compounds (e.g., 5a, 5b, 5g) were significantly more water-soluble than CB30865 (636 μM for 5a at pH 6 and 992 μM for 5g at pH 6). In addition, some of them were up to 6-fold more cytotoxic than CB30865 (e.g., for 5a, W1L2 IC50 = 0.49 ± 0.24 nM) and retained its novel biochemical characteristics.